184 related articles for article (PubMed ID: 1389933)
1. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.
Kudriakova TB; Sirota LA; Rozova GI; Gorkov VA
Br J Clin Pharmacol; 1992 Jun; 33(6):611-5. PubMed ID: 1389933
[TBL] [Abstract][Full Text] [Related]
2. Early stage autoinduction of carbamazepine metabolism in humans.
Bernus I; Dickinson RG; Hooper WD; Eadie MJ
Eur J Clin Pharmacol; 1994; 47(4):355-60. PubMed ID: 7875188
[TBL] [Abstract][Full Text] [Related]
3. Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism.
Tomson T; Svensson JO; Hilton-Brown P
Ther Drug Monit; 1989 Sep; 11(5):533-9. PubMed ID: 2815227
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose.
Vree TB; Janssen TJ; Hekster YA; Termond EF; van de Dries AC; Wijnands WJ
Ther Drug Monit; 1986; 8(3):297-304. PubMed ID: 3750374
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive study of the relation between serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites with age, weight, dose, and clearances in epileptic children.
Liu H; Delgado MR
Epilepsia; 1994; 35(6):1221-9. PubMed ID: 7988515
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics: time-dependent changes--autoinduction of carbamazepine epoxidation.
Bertilsson L; Tomson T; Tybring G
J Clin Pharmacol; 1986; 26(6):459-62. PubMed ID: 3734137
[TBL] [Abstract][Full Text] [Related]
7. Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children.
Hartley R; Forsythe WI; McLain B; Ng PC; Lucock MD
Clin Pharmacokinet; 1991 Mar; 20(3):237-46. PubMed ID: 2025982
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid-carbamazepine interaction: is valproic acid a selective inhibitor of epoxide hydrolase?
Svinarov DA; Pippenger CE
Ther Drug Monit; 1995 Jun; 17(3):217-20. PubMed ID: 7624916
[TBL] [Abstract][Full Text] [Related]
9. Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine.
Spina E; Tomson T; Svensson JO; Faigle JW; Bertilsson L
Ther Drug Monit; 1988; 10(4):382-5. PubMed ID: 3201523
[TBL] [Abstract][Full Text] [Related]
10. The 10,11-epoxide-10,11-diol pathway of carbamazepine in early pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, comedication, and relation to outcome of pregnancy.
Omtzigt JG; Los FJ; Meijer JW; Lindhout D
Ther Drug Monit; 1993 Feb; 15(1):1-10. PubMed ID: 8451773
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent pharmacokinetics of carbamazepine in rats: determination of the formation clearance of carbamazepine-10,11-epoxide.
Remmel RP; Sinz MW; Cloyd JC
Pharm Res; 1990 May; 7(5):513-7. PubMed ID: 2367320
[TBL] [Abstract][Full Text] [Related]
12. Carbamazepine-10,11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children.
Bourgeois BF; Wad N
Ther Drug Monit; 1984; 6(3):259-65. PubMed ID: 6506133
[TBL] [Abstract][Full Text] [Related]
13. Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide.
Tomson T; Tybring G; Bertilsson L
Clin Pharmacol Ther; 1983 Jan; 33(1):58-65. PubMed ID: 6848300
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of carbamazepine and its 10,11-epoxide metabolite in children.
Rane A; Höjer B; Wilson JT
Clin Pharmacol Ther; 1976 Mar; 19(3):276-83. PubMed ID: 1261166
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent metabolism of carbamazepine in humans.
Bernus I; Dickinson RG; Hooper WD; Eadie MJ
Epilepsy Res; 1996 Jul; 24(3):163-72. PubMed ID: 8832192
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of carbamazepine in psychiatric patients.
Kanarkowski R; Wankiewicz G; Lehmann W; Rybakowski J
Pol J Pharmacol Pharm; 1988; 40(1):55-61. PubMed ID: 3237559
[TBL] [Abstract][Full Text] [Related]
17. Effect of ponsinomycin on single-dose kinetics and metabolism of carbamazepine.
Couet W; Istin B; Ingrand I; Girault J; Fourtillan JB
Ther Drug Monit; 1990 Mar; 12(2):144-9. PubMed ID: 2315971
[TBL] [Abstract][Full Text] [Related]
18. Carbamazepine 10,11-epoxide in children.
Rylance GW; Edwards C; Gard PR
Br J Clin Pharmacol; 1984 Dec; 18(6):935-9. PubMed ID: 6529533
[TBL] [Abstract][Full Text] [Related]
19. Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite.
Barzaghi N; Gatti G; Crema F; Monteleone M; Amione C; Leone L; Perucca E
Br J Clin Pharmacol; 1987 Dec; 24(6):836-8. PubMed ID: 3440106
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing plasma level/dose ratios of carbamazepine and its major metabolites in epileptic children.
Hartley R; Lucock MD; Ng PC; Forsythe WI; McLain B; Bowmer CJ
Ther Drug Monit; 1990 Sep; 12(5):438-44. PubMed ID: 2293405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
